Healthcare · Medical - Healthcare Plans
Price
$415.63
Market Cap
$377.5B
Employees
400,000
Beta
0.65
Avg Volume
7,754,738
CEO
Stephen J. Hemsley
Business Description
UnitedHealth Group Incorporated (UNH) operates as a comprehensive healthcare enterprise across the United States, structuring its diverse services into four key divisions: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment provides a wide array of health benefit plans and consumer-focused services. These offerings cater to a broad spectrum of clients, including large national corporations, public sector employers, mid-sized and small businesses, and individual consumers. It also delivers specialized health coverage and wellness programs tailored for individuals aged 50 and older, addressing their needs for preventive and acute care, chronic disease management, and other age-specific health issues. This division further encompasses Medicaid plans, children's health insurance, dental benefits, and various hospital and clinical services. Optum Health focuses on delivering direct healthcare solutions and management services. It facilitates access to networks of specialist care providers, offers health management programs, direct care delivery, consumer engagement initiatives, and financial services. Its diverse clientele includes individuals (served directly through care systems), employers, insurance payers, and government organizations. Optum Insight specializes in providing technology, information, and consulting services to the healthcare industry. Its offerings include software and data products, advisory consulting arrangements, and outsourced managed services. Clients span hospital systems, physicians, health plans, governmental bodies, life sciences companies, and other relevant organizations. Finally, Optum Rx handles the company's pharmaceutical care services. This segment manages retail pharmacy networks, provides home prescription delivery, and offers specialty and compounding pharmacy capabilities. Leveraging its purchasing power and clinical expertise, Optum Rx also develops advanced programs related to step therapy, formulary management, medication adherence, and integrated disease and drug therapy management. UnitedHealth Group Incorporated, founded in 1977, has its corporate headquarters located in Minnetonka, Minnesota.
Business History
Price Overview
Last updated: Jul 1, 2026 4:35am (just now)$415.63
-4.19 (-1.00%)
Day Range
$413.25 – $422.74
52-Week Range
$234.60 – $427.93
50-Day MA
$384.99
200-Day MA
$336.24
Volume
5,633,452.00
Analyst Price Targets
Low
$361.00
Consensus
$426.75
High
$492.00
(114 analysts)
Share Structure
Outstanding
908,144,404.00
Float
905,438,134.00
Free Float
99.7%
High free float
— 99.7% of shares trade freely, ~0.3% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
APIStock Price / EPS (Diluted)
31.40
Stock Price: $415.63
EPS (Diluted): 13.23
EPS (Diluted): 13.23
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
3.19
Stock Price: $415.63
Total Equity: $94.11B
Shares: 910,000,000
Total Equity: $94.11B
Shares: 910,000,000
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
18.59
Market Cap: $377.45B
Total Debt: $78.39B
Cash: $24.37B
EBITDA: $23.06B
Total Debt: $78.39B
Cash: $24.37B
EBITDA: $23.06B
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$354.4B
Market Cap: $377.45B
Total Debt: $78.39B
Cash: $24.37B
Total Debt: $78.39B
Cash: $24.37B
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
18.5%
Gross Profit: $82.92B
Revenue: $447.57B
Revenue: $447.57B
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
4.2%
Operating Income: $18.96B
Revenue: $447.57B
Revenue: $447.57B
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
2.7%
Net Income: $12.06B
Revenue: $447.57B
Revenue: $447.57B
ROE (Profit from shareholder equity)
APINet Income / Total Equity
12.4%
Net Income: $12.06B
Total Equity: $94.11B
Total Equity: $94.11B
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
8.1%
Operating Income: $18.96B
Tax Rate: 12.9%
Equity: $94.11B
Total Debt: $78.39B
Cash: $24.37B
Tax Rate: 12.9%
Equity: $94.11B
Total Debt: $78.39B
Cash: $24.37B
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
0.79
Current Assets: $90.58B
Current Liabilities: $114.90B
Current Liabilities: $114.90B
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.83
Short-Term Debt: $6.07B
Long-Term Debt: $72.32B
Total Debt: $78.39B
Total Equity: $94.11B
Long-Term Debt: $72.32B
Total Debt: $78.39B
Total Equity: $94.11B
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$491.83
Revenue: $447.57B
Shares: 910,000,000
Shares: 910,000,000
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$103.42
Total Equity: $94.11B
Shares: 910,000,000
Shares: 910,000,000
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$17.66
Operating CF: $19.70B
CapEx: -$3.62B
Shares: 910,000,000
CapEx: -$3.62B
Shares: 910,000,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
2.6%
Last Dividend: N/A
Stock Price: $415.63
Stock Price: $415.63
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: $12.06B
Net Income: $12.06B
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares UNH against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jul 1, 2026 4:35am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $287.6B | $324.2B | $371.6B | $400.3B | $447.6B |
| Cost of Revenue | $217.9B | $244.5B | $280.7B | $310.9B | $364.7B |
| Gross Profit | $69.7B | $79.6B | $91.0B | $89.4B | $82.9B |
| Operating Expenses | $45.7B | $51.2B | $58.6B | $57.1B | $64.0B |
| Operating Income | $24.0B | $28.4B | $32.4B | $32.3B | $19.0B |
| Net Income | $17.3B | $20.1B | $22.4B | $14.4B | $12.1B |
| EBITDA | $27.1B | $31.8B | $36.3B | $28.1B | $23.1B |
| EPS | $18.33 | $21.54 | $24.12 | $15.64 | $13.23 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jul 1, 2026 4:35am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $21.4B | $23.4B | $25.4B | $25.3B | $24.4B |
| Total Current Assets | $61.8B | $69.1B | $78.4B | $85.8B | $90.6B |
| Total Assets | $212.2B | $245.7B | $273.7B | $298.3B | $309.6B |
| Current Liabilities | $78.3B | $89.2B | $99.1B | $103.8B | $114.9B |
| Long-Term Debt | $42.4B | $54.5B | $58.3B | $72.4B | $72.3B |
| Total Liabilities | $135.7B | $159.4B | $174.8B | $195.7B | $207.9B |
| Total Equity | $71.8B | $77.8B | $88.8B | $92.7B | $94.1B |
| Retained Earnings | $77.1B | $86.2B | $95.8B | $96.0B | $95.6B |
Cash Flow (Annual)
Last updated: Jul 1, 2026 4:35am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $22.3B | $26.2B | $29.1B | $24.2B | $19.7B |
| Capital Expenditure | -$2.5B | -$2.8B | -$3.4B | -$3.5B | -$3.6B |
| Free Cash Flow | $19.9B | $23.4B | $25.7B | $20.7B | $16.1B |
| Acquisitions (net) | -$4.8B | -$21.5B | -$10.1B | -$13.4B | -$4.5B |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$5.0B | -$7.0B | -$8.0B | -$9.0B | -$5.5B |
| Net Change in Cash | $4.5B | $2.0B | $2.1B | -$115.0M | $2.8B |
Analyst Estimates (Annual)
Last updated: Jul 1, 2026 4:35am (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$456.4B $444.1B – $471.6B
|
$482.1B $481.3B – $482.9B
|
$514.2B $499.2B – $527.8B
|
$549.2B $533.2B – $563.7B
|
| EBITDA |
$37.6B $36.6B – $38.8B
|
$39.7B $39.6B – $39.8B
|
$42.3B $41.1B – $43.5B
|
$45.2B $43.9B – $46.4B
|
| Net Income |
$18.1B $17.9B – $19.9B
|
$20.9B $20.7B – $25.7B
|
$27.8B $26.7B – $28.8B
|
$31.3B $30.1B – $32.4B
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jul 1, 2026 4:35am (just now)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +12.7% | +14.6% | +7.7% | +11.8% |
| Gross Profit Growth | +14.3% | +14.2% | -1.7% | -7.3% |
| Operating Income Growth | +18.6% | +13.8% | -0.2% | -41.3% |
| Net Income Growth | +16.4% | +11.2% | -35.6% | -16.3% |
| EBITDA Growth | +17.6% | +14.1% | -22.7% | -17.9% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-23 | McSweeney Erin | A-Award | 48.23 | $0.00 | $0 |
| 2026-06-23 | Noseworthy John H | A-Award | 41.00 | $0.00 | $0 |
| 2026-06-23 | GARCIA PAUL R | A-Award | 13.00 | $0.00 | $0 |
| 2026-06-23 | MONTGOMERY RICE VALERIE MD | A-Award | 41.00 | $0.00 | $0 |
| 2026-06-23 | Gil Kristen | A-Award | 8.00 | $0.00 | $0 |
| 2026-06-23 | Gottlieb Scott | A-Award | 3.00 | $0.00 | $0 |
| 2026-06-23 | Conway Patrick Hugh | A-Award | 82.49 | $0.00 | $0 |
| 2026-06-23 | Noel Timothy John | A-Award | 76.06 | $0.00 | $0 |
| 2026-06-23 | Zaetta Christopher R | A-Award | 60.69 | $0.00 | $0 |
| 2026-06-23 | DeVeydt Wayne S | A-Award | 111.76 | $0.00 | $0 |
| 2026-06-23 | HEMSLEY STEPHEN J | A-Award | 46.00 | $0.00 | $0 |
| 2026-06-23 | Stankiewicz Dennis Andrew | A-Award | 50.59 | $0.00 | $0 |
| 2026-06-23 | Baker Charles D. | A-Award | 13.00 | $0.00 | $0 |
| 2026-06-23 | MCNABB FREDERICK WILLIAM III | A-Award | 50.00 | $0.00 | $0 |
| 2026-06-23 | FLYNN TIMOTHY PATRICK | A-Award | 61.00 | $0.00 | $0 |
| 2026-06-05 | Conway Patrick Hugh | F-InKind | 686.86 | $399.47 | $274,380 |
| 2026-06-03 | Zaetta Christopher R | F-InKind | 134.02 | $377.00 | $50,526 |
| 2026-06-02 | Conway Patrick Hugh | F-InKind | 203.82 | $377.92 | $77,028 |
| 2026-04-23 | Conway Patrick Hugh | S-Sale | 800.00 | $355.00 | $284,000 |
| 2026-04-01 | HOOPER MICHELE J | A-Award | 206.00 | $0.00 | $0 |
Dividend History (Last 20)
Last updated: Jul 1, 2026 4:35am (just now)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-06-15 | $2.32 | 2026-06-03 | 2026-06-15 | 2026-06-23 |
| 2026-03-09 | $2.21 | 2026-02-24 | 2026-03-09 | 2026-03-17 |
| 2025-12-08 | $2.21 | 2025-11-07 | 2025-12-08 | 2025-12-16 |
| 2025-09-15 | $2.21 | 2025-08-13 | 2025-09-15 | 2025-09-23 |
| 2025-06-16 | $2.21 | 2025-05-23 | 2025-06-16 | 2025-06-24 |
| 2025-03-10 | $2.10 | 2025-02-24 | 2025-03-10 | 2025-03-18 |
| 2024-12-09 | $2.10 | 2024-11-06 | 2024-12-09 | 2024-12-17 |
| 2024-09-16 | $2.10 | 2024-08-07 | 2024-09-16 | 2024-09-24 |
| 2024-06-17 | $2.10 | 2024-06-05 | 2024-06-17 | 2024-06-25 |
| 2024-03-08 | $1.88 | 2024-02-23 | 2024-03-11 | 2024-03-19 |
| 2023-12-01 | $1.88 | 2023-11-08 | 2023-12-04 | 2023-12-12 |
| 2023-09-08 | $1.88 | 2023-08-23 | 2023-09-11 | 2023-09-19 |
| 2023-06-15 | $1.88 | 2023-06-07 | 2023-06-19 | 2023-06-27 |
| 2023-03-10 | $1.65 | 2023-02-27 | 2023-03-13 | 2023-03-21 |
| 2022-12-02 | $1.65 | 2022-11-04 | 2022-12-05 | 2022-12-13 |
| 2022-09-09 | $1.65 | 2022-08-17 | 2022-09-12 | 2022-09-20 |
| 2022-06-16 | $1.65 | 2022-06-08 | 2022-06-20 | 2022-06-28 |
| 2022-03-11 | $1.45 | 2022-02-16 | 2022-03-14 | 2022-03-22 |
| 2021-12-03 | $1.45 | 2021-11-05 | 2021-12-06 | 2021-12-14 |
| 2021-09-10 | $1.45 | 2021-08-11 | 2021-09-13 | 2021-09-21 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for UNH — it's generated by the pipeline (
market-narrative step).
No community reviews yet for UNH.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.360 · 7b6df9be · 2026-06-30 17:24:24